Novel Use Of Hydroxyurea in an African Region With Malaria
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2018
Price : $35 *
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms NOHARM
- 31 Aug 2018 Biomarkers information updated
- 26 Nov 2017 Status changed from active, no longer recruiting to completed.
- 22 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017.